Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
1801 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$28.65 - HK$106.00
Previous CloseN/A
Volume9.75M
Average Volume (3M)22.43M
Market Cap
$167.52B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 27, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding1,709,431,300
10 Day Avg. Volume22,788,625
30 Day Avg. Volume22,426,674
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$94.04Price Target Upside-4.04% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Cash ReservesInnovent holds a robust cash balance of RMB10.2bn, supporting its strategic initiatives and growth.
Financial PerformanceInnovent achieved profitability ahead of schedule, realizing better-than-expected profitability due to strong product revenue growth and one-off license fee income.
Next-Generation TherapiesIBI363 is positioned as a promising next-generation IO therapy with strong survival benefits, especially for IO-resistant and cold tumors.
Bears Say
Market CompetitionThe potential of IBI3003 to compete with CAR-T therapies presents a significant opportunity within the oncology drug development sector.
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$106.00 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $167.52B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 27, 2025 which is in 25 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2025. The company reported HK$0.196 earnings per share for the quarter, beating the consensus estimate of -HK$0.251 by HK$0.447.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Overvalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.14.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,709,431,300 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of HK$0.196 in its last earnings report, beating expectations of -HK$0.251. Following the earnings report the stock price went down -0.255%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.04 (-4.04% Downside)
$94.04 (-4.04% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.94%
12-Months-Change
Fundamentals
Return on Equity
-0.72%
Trailing 12-Months
Asset Growth
1.76%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
1801 Stock 12 Month Forecast
Average Price Target
HK$94.04
▼(-4.04%Downside)
Technical Analysis
Sino Biopharmaceutical
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
7.69%
Mutual Funds
― Other Institutional Investors
84.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---